Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer

Web Exclusives - FDA Oncology Update

On May 27, 2021, the FDA accelerated the approval of piflufolastat F-18 (Pylarify; Progenics Pharmaceuticals) injection, the second radioactive, prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging drug used for the diagnosis of suspected prostate cancer recurrence or metastasis.

Piflufolastat F-18 is indicated for PET diagnosis of PSMA-positive lesions in men with prostate cancer and suspected metastasis who are candidates for initial definitive therapy and for those with suspected prostate cancer recurrence, based on elevated serum prostate-specific antigen (PSA) levels. Last December, the FDA approved the first PSMA-targeted imaging drug, Ga-68 PSMA-11.

“Conventional imaging has significant limitations in detecting prostate cancer, both in initial staging and when the cancer has recurred or spread after initial primary treatment,” said Michael J. Morris, MD, Prostate Cancer Section Head, Genitourinary Medical Oncology, Memorial Sloan Kettering Cancer Center, and lead investigator in the CONDOR clinical trial. He noted that piflufolastat F-18 injection “can detect the spread of disease well before standard imaging and can be a transformative diagnostic tool.”

The FDA approval of piflufolastat F-18 was based on 2 prospective clinical trials that together included 593 men with prostate cancer who received 1 injection of piflufolastat F-18. The first study included 268 patients with prostate cancer who had PET or computed tomography (CT) scans after receiving piflufolastat F-18. The patients were candidates for resection of the prostate gland and pelvic lymph nodes and were at higher risk for metastasis. Among those who proceeded to surgery, metastatic cancer was confirmed by surgical pathology in the patients who had positive lesions on the piflufolastat F-18 PET scan. Having this information before surgery may spare patients from undergoing needless procedures.

The second study included 208 patients with elevated serum PSA levels after initial prostate surgery or other definitive therapy that provided evidence of recurrent prostate cancer. Before undergoing the piflufolastat F-18–based PET or CT scan, the patients had baseline conventional imaging that did not show definite metastasis. The use of piflufolastat F-18 detected at least 1 positive lesion in at least 1 body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of the patients.

The diagnosis of prostate cancer recurrence or metastasis was confirmed in an estimated 85% to 87% of patients (depending on the reader) with positive lesions using piflufolastat F-18–based PET scan who had correlated tissue pathology from biopsies, baseline or follow-up imaging by conventional methods, or serial PSA levels.

The most common adverse events with piflufolastat F-18 were headache, altered taste, and fatigue.

Related Items
Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection
Online First published on May 12, 2023 in FDA Oncology Update
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.